This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / MiniMed, Abbott Partner on Dual Sensors
Business product development

MiniMed, Abbott Partner on Dual Sensors

Analysis based on 7 articles · First reported Jun 03, 2026 · Last updated Jun 03, 2026

Sentiment
70
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The expanded agreement between Medtronic — Medtronic MiniMed and Abbott Laboratories to commercialize dual glucose-ketone sensors is expected to positively impact both companies' stock prices due to the potential for improved diabetes management and prevention of diabetic ketoacidosis. This innovation could lead to increased market share and revenue in the medical device and healthcare industries.

Medical Devices Biotechnology Healthcare
Event Summary

Medtronic — Medtronic MiniMed announced an expanded agreement with Abbott Laboratories to commercialize dual glucose-ketone sensors designed to integrate exclusively with Medtronic — Medtronic MiniMed's smart dosing systems. These sensors aim to provide early, real-time detection of rising ketones to help prevent diabetic ketoacidosis (DKA), a life-threatening complication for people with diabetes. The partnership builds on their existing collaboration for the Instinct sensor. Guy Dallara, CEO of Medtronic — Medtronic MiniMed, emphasized the added intelligence and protection these sensors will bring to their systems. Abbott Laboratories' dual glucose-ketone system has received CE Mark and is currently under United States — Food and Drug Administration review in the United States, with further updates on regulatory and commercialization milestones expected.

Entities Involved
subs
Medtronic — Medtronic MiniMed
Medtronic — Medtronic MiniMed announced an expanded agreement with Abbott to commercialize dual glucose-ketone sensors, enhancing its smart dosing systems and potentially improving patient outcomes, which could positively impact its market position and stock.
Importance 100.0 Sentiment 75.0
stock
Abbott Laboratories
Abbott is collaborating with Medtronic — Medtronic MiniMed to commercialize its dual glucose-ketone sensors, expanding its reach in diabetes technology and potentially increasing revenue from its medical device segment.
Importance 90.0 Sentiment 70.0
oth
Guy Dallara
Guy Dallara, CEO of Medtronic — Medtronic MiniMed, provided commentary on the strategic importance of the partnership with Abbott, highlighting Medtronic — Medtronic MiniMed's commitment to innovation in diabetes care.
Importance 50.0 Sentiment 60.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration is currently reviewing Abbott's dual glucose-ketone system, and its clearance is necessary for commercialization in the United States.
Importance 30.0 Sentiment 0.0
cnt
United States
The United States is a key market where the dual glucose-ketone systems are currently under FDA review and not yet available for sale, indicating future commercialization potential.
Importance 20.0 Sentiment 0.0
Relationships
Abbott Laboratories related ↔ United States — Food and Drug Administration
Abbott Laboratories related ↔ United States
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.